A Novel PDE4D Inhibitor BPN14770 Reverses Scopolamine-Induced Cognitive Deficits via cAMP/SIRT1/Akt/Bcl-2 Pathway

Yulu Wang, Shichao Gao, Victor Zheng, Ling Chen, Min Ma, Shichen Shen, Jun Qu, Hanting Zhang, Mark E. Gurney, James M. O’Donnell, Ying XuFrontiers in Cell and Developmental Biology 2020 · DOI

TL;DR

This study investigates BPN14770, a novel PDE4D inhibitor, and its potential to treat cognitive deficits. By using humanized PDE4D mice and a scopolamine-induced memory impairment model, the researchers found that BPN14770 effectively reversed cognitive decline. This effect appears to be mediated by the cAMP-PKA-SIRT1-Akt-Bcl-2/Bax signaling pathway, suggesting BPN14770 as a promising therapeutic candidate for neurocognitive disorders like Alzheimer's.

What Problem Does This Paper Address?

Alzheimer's disease (AD) and other neurocognitive disorders are characterized by progressive memory and learning decline, with a significant unmet need for effective treatments. While phosphodiesterase-4 (PDE4) inhibitors have shown therapeutic potential for neuropsychiatric disorders, their development has been hampered by dose-limiting side effects, often due to a lack of subtype selectivity. This paper addresses the challenge of developing selective PDE4 inhibitors with improved safety profiles and explores the underlying mechanisms of a novel PDE4D-selective allosteric inhibitor, BPN14770, in reversing cognitive deficits. The key innovation here is the use of humanized PDE4D mice, which allows for a more accurate assessment of BPN14770's efficacy in a model that better reflects human PDE4D allosteric binding.

Methods

The study employed a multi-faceted approach:

  • Humanized PDE4D Mice: A critical step was creating a mouse model with a humanized PDE4D gene. This involved a single amino acid mutation (tyrosine to phenylalanine) in the allosteric binding site of PDE4D, mimicking the human form. This allowed for studying the effects of BPN14770, a subtype-selective allosteric inhibitor designed for human PDE4D.
  • Scopolamine-Induced Cognitive Impairment Model: Cognitive deficits were induced in these mice using scopolamine, a muscarinic antagonist known to impair memory and learning.
  • Behavioral Assays:
    • Step-Down Passive Avoidance Test: This test assesses aversive memory and the ability to avoid an unpleasant stimulus.
  • Morris Water Maze (MWM) Test: This test evaluates spatial learning and memory by requiring mice to find a hidden platform in a pool of water.
  • Quantitative Proteomics/Systems-Biology Analysis: Global proteomic analysis was performed on hippocampal and frontal cortex samples to identify proteins and pathways affected by BPN14770 treatment. This involved LC-MS/MS and label-free quantification.
  • Bioinformatic Analysis: This included Volcano plots, Venn diagrams, protein-protein interaction (PPI) network analysis (using STRING), gene ontology (GO) enrichment, and KEGG pathway analysis to understand the biological processes and signaling pathways involved.
  • Immunoblot Assay: Western blotting was used to confirm and quantify the expression levels of key proteins (SIRT1, Akt, phosphorylated Akt (pAkt), Bcl-2, and Bax) in the hippocampus.

Datasets

Not explicitly detailed as separate datasets. The study utilized data generated from their own experiments on humanized PDE4D mice and wild-type littermates. Proteomic data was analyzed using various bioinformatics databases and tools (STRING, DAVID, GeneCards).

Key Insights and Ideas

  • Humanized PDE4D Mice are Crucial: The development and use of humanized PDE4D mice were essential for accurately assessing the efficacy of BPN14770, given the species-specific differences in the allosteric binding site.
  • BPN14770 Reverses Cognitive Deficits at Low Doses: The study demonstrated that relatively low doses of BPN14770 were sufficient to reverse scopolamine-induced memory and cognitive deficits, suggesting a favorable therapeutic window.
  • A Specific Signaling Pathway is Key: The research strongly implicates the cAMP-PKA-SIRT1-Akt-Bcl-2/Bax pathway in mediating BPN14770's neuroprotective effects. This pathway is involved in regulating stress resistance, neuronal autophagy, and apoptosis.
  • Targeting PDE4D Offers a Selective Approach: The allosteric inhibition of PDE4D, rather than broad PDE4 inhibition, appears to be a promising strategy for achieving therapeutic benefits with potentially fewer side effects.
  • Proteomics Uncovered Novel Pathways: The global proteomic analysis provided a comprehensive view of how PDE4D inhibition impacts cellular pathways, revealing novel connections to neuroplasticity and neuroprotection.

Key Results

  • Behavioral Improvements: BPN14770 significantly reversed scopolamine-induced deficits in both the Step-Down Passive Avoidance Test (increasing latency to step down) and the Morris Water Maze (reducing latency to find the platform and increasing entries into the target quadrant). The minimum effective dose for the Step-Down Passive Avoidance test was 0.01 mg/kg.
  • Proteomic Changes: Proteomic analysis revealed significant alterations in protein expression in the hippocampus (325 proteins) and frontal cortex (144 proteins) following BPN14770 treatment. Notably, 33 of these differentially expressed proteins were also implicated in AD.
  • SIRT1 and Akt Modulation: BPN14770 treatment increased SIRT1 expression and the ratio of phosphorylated Akt (pAkt) to total Akt in the hippocampus. These effects were reversed by co-administration of PKA (H89), SIRT1 (sirtinol), or Akt (MK-2206) inhibitors.
  • Apoptosis Regulation: The Bcl-2/Bax ratio, an indicator of apoptosis, was reduced by scopolamine but increased by BPN14770. This effect was also counteracted by the inhibitors.
  • Inhibitor Studies: Pre-treatment with PKA (H89), SIRT1 (sirtinol), or Akt (MK-2206) inhibitors blocked the cognitive-enhancing effects of BPN14770 in behavioral tests, strongly supporting the proposed signaling pathway.

Limitations and Future Work

  • Proteomics vs. Immunoblot Discrepancies: The study noted inconsistencies between the proteomic findings and immunoblot results for Bax and Bcl-2 expression. The authors attribute this to the high-throughput nature of proteomics and suggest that immunoblot assays are crucial for verifying differentially expressed proteins.
  • Further Elucidation of Cross-Talk: While the study highlights the cAMP-PKA-SIRT1-Akt-Bcl-2/Bax pathway, future work could delve deeper into the intricate cross-talk between cAMP and mTOR pathways, particularly concerning PDE4D's role.
  • Long-Term Effects and Aging: The current study focused on sub-acute treatment. Future research could investigate the long-term effects of BPN14770 and its potential in aging populations, as suggested by the authors.
  • Broader Therapeutic Applications: The findings open avenues for exploring BPN14770's efficacy in other neurodegenerative and cognitive disorders beyond AD.

Summary updated

Abstract

A global, quantitative proteomics/systems-biology analysis of the selective pharmacological inhibition of phosphodiesterase-4D (PDE4D) revealed the differential regulation of pathways associated with neuroplasticity in memory-associated brain regions. Subtype selective inhibitors of PDE4D bind in an allosteric site that differs between mice and humans in a single amino acid (tyrosine vs. phenylalanine, respectively). Therefore to study selective inhibition of PDE4D by BPN14770, a subtype selective allosteric inhibitor of PDE4D, we utilized a line of mice in which the PDE4D gene had been humanized by mutating the critical tyrosine to phenylalanine. Relatively low doses of BPN14770 were effective at reversing scopolamine-induced memory and cognitive deficits in humanized PDE4D mice. Inhibition of PDE4D alters the expression of protein kinase A (PKA), Sirt1, Akt, and Bcl-2/Bax which are components of signaling pathways for regulating endocrine response, stress resistance, neuronal autophagy, and apoptosis. Treatment with a series of antagonists, such as H89, sirtinol, and MK-2206, reversed the effect of BPN14770 as shown by behavioral tests and immunoblot analysis. These findings suggest that inhibition of PDE4D enhances signaling through the cAMP-PKA-SIRT1-Akt -Bcl-2/Bax pathway and thereby may provide therapeutic benefit in neurocognitive disorders.
BibTeX
@inproceedings{wang2020novel,
  author = {Yulu Wang and Shichao Gao and Victor Zheng and Ling Chen and Min Ma and Shichen Shen and Jun Qu and Hanting Zhang and Mark E. Gurney and James M. O’Donnell and Ying Xu},
  title = {{A Novel PDE4D Inhibitor BPN14770 Reverses Scopolamine-Induced Cognitive Deficits via cAMP/SIRT1/Akt/Bcl-2 Pathway}},
  booktitle = {Frontiers in Cell and Developmental Biology},
  year = {2020},
  doi = {10.3389/fcell.2020.599389},
}
Figure